{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:56:17Z","timestamp":1792724177953,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.chom.2023.05.012","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:00:10Z","timestamp":1686862810000},"page":"856-860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antiviral strategies for epidemic and pandemic preparedness"],"prefix":"10.1016","volume":"31","author":[{"given":"Dirk","family":"Jochmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2023.05.012_bib1","series-title":"The True Death Toll of COVID-19","author":"WHO","year":"2023"},{"key":"10.1016\/j.chom.2023.05.012_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chom.2023.05.012_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1473-3099(21)00762-3","article-title":"Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19","volume":"22","author":"Shapiro","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2023.05.012_bib4","doi-asserted-by":"crossref","first-page":"JC92","DOI":"10.7326\/J22-0056","article-title":"In persons at risk for\u00a0poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19","volume":"175","author":"Aisenberg","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.chom.2023.05.012_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-020-01636-4","article-title":"A prospect on the use of antiviral drugs to control local outbreaks of COVID-19","volume":"18","author":"Torneri","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.chom.2023.05.012_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10081639","article-title":"Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19","volume":"10","author":"Assmus","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.chom.2023.05.012_bib7","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1021\/acs.jmedchem.0c02258","article-title":"Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2","volume":"65","author":"Dai","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chom.2023.05.012_bib8","series-title":"The Path to Paxlovid How\u00a0Pfizer Scientists Transformed an Old Drug Lead into an Oral COVID-19 Antiviral","first-page":"16","author":"Halford","year":"2022"},{"key":"10.1016\/j.chom.2023.05.012_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction","volume":"598","author":"Kaptein","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chom.2023.05.012_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41586-023-05790-6","article-title":"Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates","volume":"615","author":"Goethals","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.chom.2023.05.012_bib11","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","article-title":"Oseltamivir resistance during treatment\u00a0of influenza A (H5N1) infection","volume":"353","author":"de Jong","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2023.05.012_bib12","article-title":"Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters","author":"Abdelnabi","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.chom.2023.05.012_bib13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312823002056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312823002056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:34:22Z","timestamp":1761827662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312823002056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1931312823002056"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2023.05.012","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral strategies for epidemic and pandemic preparedness","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2023.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}